Netris' NTN1 inhibitor safe in Phase I for solid tumors

Netris Pharma S.A.S. (Lyon, France) said escalating doses of up to 20 mg/kg IV NP137 every two weeks were well tolerated with no dose-limiting toxicities (DLTs) reported in a Phase I trial in 19 patients with heavily pretreated advanced solid tumors. The company said two patients with advanced uterine cancer who received NP137 had an objective response, and several patients achieved prolonged stable disease.

Final data will be submitted for presentation at a medical meeting. The expansion portion of the open-label, French trial is enrolling 24 patients. NP137 is a humanized IgG1 mAb against netrin 1 (NTN1)...